💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

U.S. lawmakers seek missing information in review of Monsanto weedkiller

Published 08/09/2017, 10:25 AM
© Reuters. Monsanto Co's Roundup shown for sale in California

By Kate Kelland

LONDON, (Reuters) - The chairman of a congressional committee has asked the U.S. National Institutes of Health (NIH) to explain why its National Cancer Institute (NCI) failed to publish data that showed no links between glyphosate and cancer.

In a Tuesday letter seen by Reuters, U.S. Representative Trey Gowdy, who chairs the House Committee on Government and Oversight Reform (OGR), said he "is concerned about the new revelations" and is "seeking more information" about why the exculpatory results were not published by the NCI.

Glyphosate is a key ingredient in Monsanto's top-selling weedkiller Roundup.

Gowdy's letter to NIH Director Francis Collins follows a June report by Reuters which found that a senior scientist from the NCI knew that fresh data from a large research project known as the Agricultural Health Study (AHS) showed no links between glyphosate and cancer.

Draft scientific papers dating from 2013 containing the data were never published. Consequently, the information was not able to be taken into account during the March 2015 review of the pesticide by the World Health Organization's International Agency for Research on Cancer (IARC).

An NIH spokeswoman told Reuters the NIH had received Gowdy's letter "and will be responding directly to the committee."

Aaron Blair, the senior scientist at the NCI who knew about the data and also chaired the IARC review, previously told Reuters the data was not published in time because there was too much to fit into one scientific paper. Blair is now retired from the NCI.

An NCI spokeswoman told Reuters in June the institute was drafting a manuscript on this topic. It would "explore the effects of glyphosate exposure in greater depth", she said, and would be submitted to a peer-reviewed journal "in the coming months."

Gowdy's letter asked for "a briefing on these issues as soon as possible". It also asked for information and any documents relating to the unpublished AHS data on glyphosate.

No one at IARC, which is based in Lyon, France, was immediately available for comment late on Tuesday.

IARC concluded in 2015 that glyphosate, is a "probable human carcinogen." It based its finding on "limited evidence" of carcinogenicity in humans and "sufficient evidence" in experimental animals.

The agency's assessment is at odds with other international regulators who have said the weedkiller is not a carcinogenic risk to humans.

The OGR has been looking into U.S. taxpayer funding of IARC. It began investigating IARC's operations in 2016 after several lawmakers raised questions about why U.S. taxpayers were funding an agency that often faces criticism for its work.

A letter by Jason Chaffetz, then chairman of the OGR, in September 2016, also addressed to the NIH director, described IARC as having "a record of controversy, retractions, and inconsistencies" and asked why the NIH continued to fund it.

In previous responses to questions about its assessments of glyphosate and many other substances, IARC has defended them as scientifically sound.

© Reuters. Monsanto Co's Roundup shown for sale in California

The agency says its "monographs" - the name it gives its classifications of carcinogens - are "widely respected for their scientific rigor, standardized and transparent process and ... freedom from conflicts of interest".

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.